Your Yourlocation: Home > Explore the possibility of tiotropium bromide(136310-93-5) as a treatment for asthma

Boehringer Ingelheim claims today that tiotropium bromide(136310-93-5), produced by standard care in patients with a wide range of symptomatic conditions, achieved a significant improvement in the time to first exacerbation of severe asthma and the time to first exacerbation of asthma Good Phase III trial, which was administered via the Respimat Soft Mist inhaler once a day.

Boehringer Ingelheim pointed out that the results were compared with the placebo group, the group given only standard care, that inhaled corticosteroid hormones, and long-acting β2 agonists, and the results with age, allergies, smoking, and bronchodilator response.

Boehringer Ingelheim also released preliminary results based on a subset of PrimoTinA-asthmaTM pre-planned data from the American College of Thoracic Surgery in Philadelphia.

"This result is very encouraging, considering that we are continuing to explore the possibility of tiotropium bromide(136310-93-5) as a treatment for asthma," said Richard Russell, MD, Waxham Park Hospital, Consultant, Chest Physician, Royal College of Physicians "Despite a number of treatment options, a significant number of asthmatic patients are still symptomatic," said British investigator PrimoTinA-asthma. "The findings suggest that tiotropium bromide(136310-93-5) may be an effective treatment option."

In the report by Boehringer Ingelheim, Professor David Halpin, PhD, Professor of Respiratory Medicine, Royal Devon and Exeter Hospital, UK, said: "Patients in PrimoTinA-asthma are all asthma patients and not COPD patients." According to age at onset, The duration of symptoms, smoking status, allergies, and bronchodilator response.Titropium bromide was shown to be as effective as asthma in COPD patients.

PrimoTinA-asthmaTM study of two groups of parallel test, a group of patients between the ages of 18-75 asthma patients, before the age of 40 more than 5 years of history of asthma diagnosis; another group of non-smokers, or who have 10 years Smoking less than 1 pack a day, but 1-2 years before the start of the trial have quit.

In a 48-day trial, 456 patients were randomized equally into 2 groups, one receiving tiotropium bromide(136310-93-5) inhalation, and the other receiving placebo. Patients were also allowed to receive additional background therapies, including theophylline, antiallergic agents, stable systemic steroids and omeprazol.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved